Trial Results Find Enfortumab Vedotin-ejfv, Pembrolizumab Combination Effective in Urothelial Cancer
September 28th 2023The combined enfortumab vedotin-ejfv and pembrolizumab treatment is recommended for patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing therapy.
Read More
FDA Approves Gepirone Extended-Release for Treatment of Major Depressive Disorder
September 28th 2023Gepirone hydrochloride ER (Exxua; Fabre-Kramer Pharmaceuticals Inc) is in a new class of antidepressants, making it the first and only approved antidepressant that selectively targets serotonin 1A receptors.
Read More
Possible Link Between Depression, Limited Social Interactions During COVID-19 Pandemic
September 28th 2023Study findings showed a 10% increase in the proportion of individuals staying home due to COVID-19 policy restrictions being associated with a 0.27 increase in PHQ-9 scores for depression.
Read More
Independent Pharmacy Files Lawsuit Against CVS Health, Caremark, Aetna Based on DIR Fees
September 28th 2023The National Community Pharmacists Association said the action was sent into motion by wrongful penalties for Medicare Part D prescriptions, called pharmacy direct and indirect remuneration fees.
Read More
Bosutinib Approved by FDA for Pediatric Patients With Chronic Myelogenous Leukemia
September 27th 2023Bosutinib (Bosulif) is indicated to treat pediatric patients with Philadelphia chromosome–positive chronic-phase chronic myelogenous leukemia that is newly diagnosed, resistant, or intolerant to previous therapy.
Read More
Large Review Suggests IVIG is Effective for Neurological Diseases Following COVID-19 Infection
September 27th 2023Intravenous immunoglobulin found to provide fast and long-lasting relief for COVID-19-related neurological conditions, although investigators are still uncovering the pathology of many of these conditions.
Read More
Enfortumab Vedotin-ejfv, Pembrolizumab Combination Shows Promise Treating Urothelial Cancer
September 26th 2023Investigators reported that enfortumab vedotin-ejfv (Padcev; Astella Pharma Inc, Seagen Inc) in combination with pembrolizumab (Keytruda; Merck & Co Inc) met the dual primary endpoints of overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer.
Read More